Clinical Advances in Ustekinumab in the Treatment of Crohn's Disease
As the study of inflammatory bowel disease (IBD) advances, various biological agents for IBD are emerging, ushering in a new area of IBD treatment. Ustekinumab, an anti-interleukin-12/23 agent, is a new option for Crohn's disease patients with prior failure of traditional pharmacological treatm...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Chinês |
| Vydáno: |
Chinese General Practice Publishing House Co., Ltd
2022-09-01
|
| Edice: | Zhongguo quanke yixue |
| Témata: | |
| On-line přístup: | https://www.chinagp.net/fileup/1007-9572/PDF/1658996860121-474947965.pdf |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|